Services
- Business Interruption & Commercial Disputes
- Class Action Defense
- Complex Litigation
- E-Discovery
- Federal Claims
- Financial Institutions
- Government Investigations, White Collar & Civil Defense
- Insurance Coverage
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- Risk Mitigation & Management
- Transportation
Education
George Washington University Law School (J.D., 1994, with high honors, Order of the Coif) Southern Methodist University (B.A., 1991)Admissions
- District of Columbia
- Maryland
- Montana
- United States Courts of Appeals for the Second, Fourth, Fifth, Sixth, Ninth, and Eleventh Circuits
- United States District Courts for the District of Columbia, District of Maryland, District of Montana, and District of Nebraska
- United States Court of Federal Claims
Accolades
- “Robert Johnston is an excellent lawyer. He is a strong litigator and is very highly regarded. I really like him.”
–Client | Chambers USA - “Robert Johnston is a creative and outstanding lawyer. I can’t say enough, he was really exceptional.”
–Third Party | Chambers USA - Lawdragon 500 Leading Litigators in America, 2024, 2025
- Super Lawyers, Civil Litigation Defense, 2021-2024
- BTI Client Service All-Star, 2020
- AV Preeminent Lawyer by ALM Media and Martindale-Hubbell, 2014-2024
- Corporate America Legal Elite for Best in Product Liability Litigation-Washington, DC, 2015
- Litigation Counsel of America, Fellow
Memberships
- National Association of Railroad Trial Counsel (NARTC)
- NARTC’s College of Railroad Trail Advocacy, Faculty Member
- Defense Research Institute
- The Sedona Conference
- The George Washington Law Review
Insights & Events
The dismissal is a victory that informs the court of the potential meritless claims and cases across the MDL inventory.
Robert Johnston and Eric Lasker Named to the 2025 Lawdragon 500 Leading Litigators in America
news | September 11, 2024Per Lawdragon, attorneys on the list are "the best litigators the U.S. has to offer in . . . complex civil litigation.”
Robert Johnston and Gary Feldon Present CLE Webinar on New Federal Rule Governing MDLs
event | October 10, 2024Firm partners Gary Feldon and Robert Johnston presented in a Strafford live webinar on the new federal Rule 16.1 governing Multidistrict Litigation case management. MDLs account for 70 percent of all civil cases in federal court. …
Litigation and Compliance Impacts of Proposed Ethylene Oxide Regulations Based on Flawed Science
news | June 18, 2024Co-authored by Robert E. Johnston and Aleksandra Rybicki
“New Rule on MDLs Should Prompt Courts to Reevaluate Involvement in Settlement,” The AmLaw Litigation Daily
news | May 7, 2024Robert Johnston and Gary Feldon discuss how the proposed Federal Rule of Civil Procedure on multidistrict litigation—the first rule specific to MDLs—has put a spotlight on MDL judges’ proper role in settlement.
Congratulations to all of our Super Lawyers and Rising Stars
By Robert E. Johnston and Gary Feldon
Robert E. Johnston Speaks on Ethylene Oxide Litigation at DRI Toxic Torts & Environmental Law Seminar
event | March 22, 2024At DRI’s recent Toxic Torts & Environmental Law Seminar, firm partner Robert Johnston spoke on a panel addressing litigation and compliance impacts of proposed ethylene oxide regulations based on flawed science. The panel discussed the misleading…
Proposed Federal Rule on MDLs Gives Parties Opportunity to Advance Merits-Driven Case Management
publication | March 15, 2024Hollingsworth LLP attorneys Robert Johnston, Gary Feldon, and Stephanie Salek address the MDL system's widespread injustice and inefficiency in a Legal Backgrounder for Washington Legal Foundation.
Bloomberg Law: “Multidistrict Litigation Rule Should Drive Merits-Based Results”
publication | March 7, 2024By Robert E. Johnston and Gary Feldon
Hollingsworth LLP Recognized in 2023 Annual Report for its Membership on Advisory Council to DRI’s The Center
news | February 16, 2024This year, Hollingsworth LLP became the first law-firm member of the Advisory Council to DRI’s The Center for Law and Public Policy (“the Center”). Firm Partner Robert E. Johnston represents the firm on the Council and…
Draft Federal Rule of Civil Procedure 16.1 Should Do More to Promote Just and Efficient Management of Multidistrict Litigation
news | February 2, 2024Hollingsworth LLP’s Robert E. Johnston and Gary Feldon submit comment to the Committee on Rules of Practice and Procedure.
Robert Johnston Appointed to Key Committees at DRI’s Center for Law and Public Policy
news | October 1, 2023Firm partner Robert Johnston has been appointed to two key committees at DRI’s Center for Law and Public Policy. He will serve on the Legislation and Rules Committee as well as on the Center’s Third-Party Litigation…
Following Illinois Trial Victory, Robert Johnston and Aleksandra Rybicki Publish on Ethylene Oxide (EO)
publication | July 28, 2023In “Ethylene Oxide: How Dubious Regulatory Science Has Fueled Vicious Cycle of Litigation and Overregulation”, published by Washington Legal Foundation, the authors discuss the litigation and regulatory environment for companies using EO. Robert served as lead…
Firm Partners Robert Johnston and Matthew Malinowski Speak at NARTC’s 69th Annual Meeting
event | July 26, 2023Firm partners Robert Johnston and Matt Malinowski spoke at the 69th annual meeting of the National Association of Railroad Trial Counsel (NARTC) in Boulder, CO. They presented on replication errors in their presentation “Alternative Cause and…
The Firm congratulates fifteen attorneys named as 2023 Super Lawyers and Rising Stars for Washington, DC. The annual publication lists the top five percent of attorneys in each state, as chosen by their peers through a…
Firm Contributes Chapter on Opioid Litigation and Daubert to Karch’s Drug Abuse Handbook
news | January 15, 2023This compendium is considered the quintessential text addressing the pharmacological, medical, and legal aspects of drugs, and informing the forensic community of the latest scientific advances and emergent practices.
Hollingsworth LLP Major Defense Win in Ethylene Oxide Trial in Cook County, Illinois
news | November 18, 2022On November 18, 2022, a Cook County, Illinois jury returned a verdict in favor of Firm clients Sterigenics and Sotera Health, LLC after a twenty-eight day trial involving a plaintiff’s claims that emissions of ethylene oxide…
Hollingsworth LLP partner Robert E. Johnston argued against centralization of claims against Novartis in In re Tasigna Products Liability Litigation before the Judicial Panel on Multidistrict Litigation.
Robert Johnston Speaks on Federal Preemption in Pharmaceutical Litigation at WLF Forum
news | June 10, 2021Called upon to solve clients’ most challenging problems, Mr. Johnston often handles high-profile, landmark cases, presenting cutting-edge litigation theories and defenses for some of the nation's largest companies.
Robert leads the Firm's practice group in this quickly evolving area.
In innovator liability case win, Firm client Novartis Pharmaceuticals is represented by Robert Johnston, Matt Malinowski, and Shannon Proctor.
Congratulations to Robert Johnston who has been named a 2020 “Client Service All-Star” by BTI Consulting Group. According to clients, “Mr. Johnston understands what we value and how to help us accomplish our goals.” “I appreciate…
In Reclast case, Novartis obtains summary judgment based on Daubert exclusion of causation experts’ testimony.
news | February 10, 2017February 2017 — Hollingsworth LLP flexed its considerable Daubert muscle once again in serial pharma litigation in Jones v Novartis. With the benefit of extensive briefing by Firm partners Stephen A. Klein and Robert E. Johnston, and…
— Robert Johnston for DRI's Product Liability Committee Newsletter
Robert Johnston and Donald Fowler Selected Best in Pharmaceutical Products Liability Litigation-Washington, DC.
news | August 20, 2015Corporate America magazine has unveiled the Legal Elite 2015 Award winners, naming Robert E. Johnston and now-retired partner Donald W. Fowler Best in Products Liability Litigation – Washington DC. Across the country, the Legal Elite Awards…
Robert Johnston and Matt Malinowski serve as faculty at the National Association of Railroad Trial Counsel (NARTC) trial advocacy college.
news | June 1, 2015Firm partners Robert E. Johnston and Matthew J. Malinowski were invited by the NARTC to join the faculty at their annual trial advocacy college during the first week of June 2015 in Dallas, Texas. Founded over sixty years…
Effective Tactics for Opposing Certification from Recent Food Labeling Class Actions
publication | August 1, 2014For WLF Legal Backgrounder, by Firm partner Robert Johnston.
Firm partner Robert E. Johnston discusses third-party litigation funding at the 2014 Winter Meeting of the National Association of Railroad Trial Counsel.
news | March 14, 2014On March 12, 2014, at the 2014 Winter Meeting of the National Association of Railroad Trial Counsel (NARTC) in Phoenix, Robert Johnston spoke to attendees on the growing problems associated with the funding of plaintiffs’ suits…
St. Louis Federal Jury Returns Verdict for Novartis in Second Zometa Defense Verdict in a Week
news | February 1, 2012On two consecutive days, two different federal juries returned defense verdicts in favor of Firm client Novartis Pharmaceuticals Corporation in trials arising out of the federal MDL litigation pending in the Middle District of Tennessee, In re…
Four Firm partners credited for summary judgment decision in N.D. Ga. products liability case.
news | January 11, 2012DRI's The Voice
Hollingsworth LLP secures major defense verdict for client Novartis in federal Aredia®/Zometa® trial.
news | May 25, 2011After less than five hours of deliberation, a Brooklyn, New York federal jury on May 25, 2011, returned a verdict in favor of Novartis Pharmaceuticals Corporation in a seven-day trial involving Aredia® and Zometa®, bisphosphonate drugs…
On April 1, 2010, Judge Jessica Mayer, Mass Tort Judge for the New Jersey Superior Court in Middlesex County, granted firm client Novartis Pharmaceutical Corporation’s motion to exclude the testimony of plaintiff’s case-specific expert Dr. Joseph…
Court grants Firm client Novartis Pharmaceuticals Corporation summary judgment in case selected for first wave of trials in New Jersey Aredia® and Zometa® Mass Tort action.
news | April 12, 2010On April 1, 2010, Judge Jessica Mayer, Mass Tort Judge for the New Jersey Superior Court in Middlesex County, granted firm client Novartis Pharmaceutical Corporation summary judgment in Walsh v. Novartis Pharmaceutical Corporation. Click here to view opinion. Plaintiff…
Sixth Circuit affirms grant of summary judgment in favor of Firm client Novartis in five cases brought by non-U.S. plaintiffs.
news | November 24, 2009On November 24, 2009, the United State Court of Appeals for the Sixth Circuit affirmed the grant of summary judgment in favor of Firm client Novartis Pharmaceuticals Corporation (“NPC”) in five cases brought by plaintiffs who…
Sixth Circuit affirms grant of summary judgment in favor of Firm client Novartis in three cases based on Michigan law.
news | November 24, 2009On November 24, 2009, the United State Court of Appeals for the Sixth Circuit affirmed the grant of summary judgment in favor of firm client Novartis Pharmaceuticals Corporation in three cases brought by residents of Michigan…
MDL court grants Summary Judgment in four first-wave Zometa cases; Case No. 3:08-1157 (Anderson), Case No. 3:08-1156 (Melau), Case No. 3:06-0377 (Thomas).
news | October 28, 2009Case No. 3:08-1157, Anderson. In the first wave of cases in the In re Aredia and Zometa Products Liability Litigation, Chief Judge Todd Campbell of the United States District Court for the Middle District of Tennessee granted summary…
Federal Court grants summary judgment filed by Firm client Novartis Pharmaceuticals Corporation in five suits brought by foreign plaintiffs.
news | February 2, 2009On December 2, 2008, Chief Judge Todd J. Campbell of the United States District Court for the Middle District of Tennessee granted summary judgment to Firm client, Novartis Pharmaceuticals Corporation (NPC), in five lawsuits brought by…
Judicial Panel on Multidistrict Litigation re-transfers two cases to Aredia®/Zometa® MDL over plaintiffs’ objections.
news | December 3, 2008On December 3, 2008, the federal Judicial Panel on Multidistrict Litigation issued an order transferring two actions pending against a Firm client, Novartis Pharmaceuticals Corporation (NPC), back to the Aredia®/Zometa® MDL over the objections of the…
Federal Court grants summary judgment based on product identification to Firm client Novartis Pharmaceuticals Corporation.
news | September 29, 2008On September 29, 2008, Chief Judge Todd J. Campbell of the United States District Court for the Middle District of Tennessee granted summary judgment to Firm client, Novartis Pharmaceuticals Corporation (NPC), in a lawsuit alleging that…
Cases
The Zometa Cases
- Precedent
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- Class Action Defense
- January 27, 2015
The core business model for products-liability plaintiffs’ lawyers depends increasingly on first amassing an inventory of claimants via consolidated state and federal proceedings, and then threatening big verdicts in early trials involving cherry-picked claims in favorable…
Hollingsworth LLP Secures a 12(b)(6) Dismissal for Horizon Therapeutics USA, Inc.
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- October 28, 2024
The case is In Re: Tepezza Marketing, Sales Practices, and Products Liability Litigation, Case Number 1:23-cv-03568, U.S.D.C. N.D. Ill.
Hollingsworth LLP Secures Major Defense Verdict for Sterigenics and Sotera Health in Cook County, Ill. Trial
- Verdict
- Products Liability & Toxic Torts
- November 18, 2022
A Cook County, Illinois jury returned a verdict in favor of Firm clients Sterigenics and Sotera Health, LLC after a twenty-eight day trial involving a plaintiff’s claims that emissions of ethylene oxide from Sterigenics medical-device sterilization…
5th Circuit Affirms Novartis Summary Judgment in Tegretol Innovator Liability Case
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- February 5, 2021
The court affirmed the Western District of Texas’s dismissal of plaintiff’s innovator liability claims under FRCP 12(b)(6).
Idaho Court Dismisses Innovator Liability Claims Against Novartis for Lack of Specific Personal Jurisdiction
- Case
- Pharmaceutical & Medical Device
- July 13, 2020
The District Court of the Fourth Judicial District of the State of Idaho dismissed an innovator liability claim against Firm client Novartis Pharmaceuticals Corporation (“NPC”) for lack of specific personal jurisdiction. The court found that NPC’s…
Federal Court Holds N.J. Statute Precludes Punitive Damages and “fraud” Exception is Preempted
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- July 31, 2018
A federal district court judge has precluded plaintiffs from seeking punitive damages at trial in a product liability case involving one of Novartis Pharmaceuticals Corporation’s cancer therapies. On July 31, 2018, Judge Robin L. Rosenberg of…
11th Circuit Affirms Summary Judgment in Reclast Case Based on Daubert Exclusion of Expert Testimony
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- April 30, 2018
The Eleventh Circuit affirmed Novartis’s summary judgment win in Jones v. Novartis Pharm. Corp., No. 17-1106 (11th Cir. Apr. 30, 2018). The Court, in a per curiam opinion issued only three weeks after oral argument, affirmed…
Novartis Obtains Summary Judgment on Daubert Exclusion of Expert’s Testimony in Reclast Case
- Case
- Products Liability & Toxic Torts
- February 10, 2017
Judge Virginia Hopkins of the U.S. District Court for the Northern District of Alabama granted Novartis’s motion for summary judgment and entered final judgment in Jones v. Novartis Pharmaceuticals Corp., No. 2:13-cv-00624-VEH, 2017 WL 553134 (N.D.…
Significant Victory for Porter Hayden in Asbestos Coverage Dispute over Exhaustion of Insurers’ Excess Policies
- Case
- Insurance Coverage
- January 2, 2014
Porter Hayden prevailed on a significant coverage dispute when the U.S. District Court for the District of Maryland confirmed that Maryland’s “horizontal exhaustion” rule requires only exhaustion of the primary policies in a particular year on…
Novartis Wins Again
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- September 6, 2013
Three weeks before a scheduled trial, the U.S. District Court for the Eastern District of Tennessee granted summary judgment for Novartis Pharmaceuticals in Payne v. Novartis Pharm. Corp., No. 1:12-CV-77 (E.D. Tenn. Sept. 6, 2013). Senior…
New Jersey Jury Finds No Failure to Warn in Zometa Suit
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- May 15, 2013
After deliberating for fewer than six hours, a New Jersey jury returned a 7-to-1 verdict in favor of Novartis Pharmaceuticals Corporation in a thirteen-day trial involving Zometa, a bisphosphonate drug given to cancer patients suffering metastases…
Novartis Wins Summary Judgment in Rhode Island Aredia Case
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- December 19, 2012
Chief Judge Mary Lisi of the U.S. District Court for the District of Rhode Island adopted Magistrate Judge Lincoln Almond’s recommendation and entered judgment in favor of Novartis in Patterson v. Novartis Pharm. Corp., No. 1:11-402-ML-LDA…
In Major Precedent for Drugmakers, Federal Court Precludes Punitives Under New Jersey Law
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- September 5, 2012
Zimmerman v. Novartis Pharm. Corp., No. 8:08-cv-02089-RWT (D. Md. Sept, 5, 2012)
Second Circuit Affirms Defense Verdict in Favor of Novartis
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- August 29, 2012
The Second Circuit affirmed a defense verdict in Hogan v. Novartis Pharm. Corp., 1:06-260-BMC (E.D.N.Y.). On appeal, plaintiff/appellant argued that the district court erred in denying her last-minute request to present testimony from a treating oral…
E.D. Missouri Grants Novartis Summary Judgment in Products Liability Case
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- June 19, 2012
The U.S. District Court for the Eastern District of Missouri granted Novartis Pharmaceuticals Corporation’s Daubert motion regarding plaintiff’s expert witnesses and then granted summary judgment in favor of Novartis in Parmentier (Johnson) v. Novartis Pharm. Corp., No.…
Federal Court in Pharma Litigation Excludes Most of Plaintiff’s Expert’s Proffered Testimony
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- March 21, 2012
Judge Graham Mullen ruled on Novartis’s Daubert motion in a Zometa case, excluding large portions of the opinions of Dr. Suzanne Parisian. Lemons v. Novartis Pharm. Corp., No. 3:08-cv-00361 (W.D.N.C. Order March 21, 2012). Dr. Parisian…
Porter Hayden wins ruling that insurance coverage is an asset surviving bankruptcy and defeats insurer’s motion to indemnify Porter Hayden only for actual, discounted payments of its bankruptcy-settlement trust.
- Case
- Insurance Coverage
- March 6, 2012
On March 6, 2012, the United States District Court for the District of Maryland ruled in favor of arguments made by Hollingsworth LLP, that insurance coverage is an asset surviving bankruptcy and that Porter Hayden Company…
Sandoz Exits MDL After E. D. New York Finds Product Liability Claims Preempted
- Case
- Pharmaceutical & Medical Device
- Products Liability & Toxic Torts
- January 30, 2012
The U.S. District Court for the Eastern District of New York granted summary judgment in favor of firm client Sandoz Inc., along with APP Pharmaceuticals, Inc., Ben Venue Laboratories, Inc., Teva Parenteral Medicines, Inc., and Hospira,…
Judge William Duffey of the U.S. District Court for the Northern District of Georgia granted summary judgment in favor of Firm client Novartis Pharmaceuticals Corporation in a case alleging that plaintiff’s treatment with Novartis’s drugs Aredia…
Sixth Circuit Affirms Summary Judgment Based on Statutory Presumption Created by Florida Law
- Case
- Complex Litigation
- Pharmaceutical & Medical Device
- August 23, 2011
In Emerson v. Novartis Pharm. Corp., No. 09-6273, 2011 WL 3701835 (6th Cir. Aug. 23, 2011), the Sixth Circuit affirmed a grant of summary judgment based upon a statutory presumption created by Florida law. Florida has…
Sixth Circuit Affirms Summary Judgment in Three Cases for Firm Client Novartis
- Case
- Pharmaceutical & Medical Device
- August 23, 2011
In 2011, the Sixth Circuit affirmed summary judgment for Novartis in three cases, in which plaintiffs had no retained experts on the subject of specific causation, i.e., did Aredia and/or Zometa cause plaintiffs to develop osteonecrosis…
Eastern District of New York Excludes Entire Testimony from Plaintiff”s Purported Regulatory and Warnings Expert
- Case
- Pharmaceutical & Medical Device
- May 3, 2011
Hogan v. Novartis Pharm. Corp., 1:06-cv-00260-BMC-RER (E.D.N.Y. May 3, 2011)